Evidence map›Paper›PMID 26261536›Full record

ArticleInternational journal of clinical and experimental pathology2015

Aberrant LRP16 protein expression in primary neuroendocrine lung tumors.

Yun Shao, Xiaoying Li, Yali Lu, Lin Liu, Po Zhao

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yun ShaoDepartment of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China ; Department of Pathology, Chinese People's Liberation Army (PLA) 307 Hospital China.
Xiaoying LiDepartment of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Yali LuDepartment of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Lin LiuDepartment of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Po ZhaoDepartment of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Chinese PLA General Hospital · CN307th Hospital of Chinese People’s Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Leukemia related protein 16 gene (LRP16) localized on chromosome 11q12.1, is an important estrogen-responsive gene and a crucial regulator for NF-kB activation. LRP16 is frequently expressed in human cancers; however, the LRP16 gene remains unexplored in lung neuroendocrine tumors. The aim of this study was to investigate the role of LRP16 expression in primary lung neuroendocrine tumors.

methodslung neuroendocrine tumors were analyzed for LRP16 gene expression by two-step non-biotin immunohistochemical method.

resultsFifty of ninety (55.6%) cases of neuroendocrine lung tumors tested were positive for LRP16 protein by immunohistochemistry. The expression of LRP16 was mainly located in cytoplasm and nucleus of tumor cells. LRP16 protein was corresponding to tumor type and clinical stage, as well as survival time.

conclusionsThe results indicate that abnormal LRP16 expression is noted in neuroendocrine lung tumors and the expression can give insight into the pathogenesis of the disease. The LRP16 protein may serve as a potential marker in predicting prognosis of neuroendocrine lung tumors.

Indexed as

Biomarkers, TumorCarboxylic Ester HydrolasesCarcinoma, NeuroendocrineFemaleHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm ProteinsNeoplasm StagingProportional Hazards ModelsRisk FactorsTime FactorsBiomarkers, TumorCarboxylic Ester HydrolasesMACROD1 protein, humanNeoplasm ProteinsimmunohistochemistryLRP16Neuroendocrine lung tumorsprognosis

Identifiers

PMID26261536
PMCPMC4525870
OpenAlexW1487033997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.